Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Cohort Studies
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
In Situ Hybridization, Fluorescence
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma
Neoplasm Staging
Prognosis
Proportional Hazards Models

authors with profiles

Andrzej Jakubowiak